Co‐administration of kla‐TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice. (18th May 2018)
- Record Type:
- Journal Article
- Title:
- Co‐administration of kla‐TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice. (18th May 2018)
- Main Title:
- Co‐administration of kla‐TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice
- Authors:
- Hu, Cuihua
Chen, Xiaolong
Huang, Yibing
Chen, Yuxin - Abstract:
- Abstract: To enhance the anticancer activity, tumor penetration ability of the hybrid anticancer peptide, in this study, a TAT (RKKRRQRRR) peptide modified kla peptide (KLAKLAKKLAKLAK, with all D‐amino acids), named kla‐TAT, was co‐administrated with the homing/penetrating peptide iRGD which could enhance the permeability of chemical drug in solid tumor and tumor vessel by co‐administration. In this study, the nonsmall cell lung cancer A549 cell line with the iRGD targeting receptor neuropilin‐1 high expression was selected to establish the 2D monolayer cell, 3D multiple cell spheroids, and xenograft mice model. The co‐administration of iRGD strengthened the permeability of kla‐TAT peptide against A549 2D and 3D sphere model with the penetration improvement property of iRGD; more importantly, co‐administration with iRGD dramatically enhanced the accumulation of kla‐TAT peptide in tumor tissue on the xenograft mice model with the homing property of iRGD. The co‐administration of iRGD strategy confers targeting ability to the hybrid peptide kla‐TAT. We believe the chemical conjugation plus co‐administration approach may provide a promising way for cancer treatment in clinical practices. Abstract : The co‐administration of iRGD strengthened the permeability of kla‐TAT peptide against A549 2D monolayer cell model and 3D multiple sphere cell model as well as dramatically enhanced the accumulation of kla‐TAT peptide in tumor tissue on the A549 xenograft mice model.
- Is Part Of:
- Chemical biology & drug design. Volume 92:Number 2(2018)
- Journal:
- Chemical biology & drug design
- Issue:
- Volume 92:Number 2(2018)
- Issue Display:
- Volume 92, Issue 2 (2018)
- Year:
- 2018
- Volume:
- 92
- Issue:
- 2
- Issue Sort Value:
- 2018-0092-0002-0000
- Page Start:
- 1567
- Page End:
- 1575
- Publication Date:
- 2018-05-18
- Subjects:
- accumulation -- co‐administration -- iRGD -- kla‐TAT -- permeability
Drugs -- Design -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
615.19005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01253034-000000000-00000 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1747-0285 ↗
http://www.blackwell-synergy.com/loi/jpp ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cbdd.13323 ↗
- Languages:
- English
- ISSNs:
- 1747-0277
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3139.120000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 14181.xml